drugset / Trial / NCT06233942
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
Timeline
- Start
- 2024-04-12
- Primary completion
- 2027-09-28
- Completion
- 2028-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG-C9074 | Unknown | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |